Epidemiology of Inflammatory Bowel Disease in a Cohort of US Black Women - Anyane-Yeboa, Adjoa; Buadu, Maame Araba E.; Khalili, Hamed; Cozier, Yvette (medRxiv, 2022)
Background and Aims Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease are inflammatory diseases of the gastrointestinal tract. The incidence of IBD is increasing in minority populations; however, little is known about the epidemiology and disease characteristics of IBD in Black women.Methods Our study population included participants in the Black Women’s Health Study. Diagnosis of IBD was self-reported through the biennial questionnaires starting at baseline in 1995. We estimated the incidence of IBD according to age and geographic region. A follow up supplementary questionnaire was also sent to a subset of participants who reported diagnosis of IBD to evaluate the accuracy of self-reported diagnosis and to assess disease characteristics.Results Through December 31st 2021, a total of 609 cases of IBD were reported, of which 142 were prevalent at baseline (prevalence = 0.24%) and 467 were incident (crude incidence rate = 33.2/100, 000 person-years). The incidence of IBD was highest in the <30 years age group and similar across geographic region. Among the participants who responded to the supplementary questionnaire, 62.1% had confirmed diagnosis of IBD.Conclusions In a large prospective cohort of US Black women, we found that the incidence of IBD was similar to previously published estimates in US White women. Future studies should focus on identifying risk factors for IBD in Black individuals in the US.Background The incidence of IBD is increasing in minorities.Findings The prevalence and incidence of IBD in the BWHS are higher than previously reported in other cohort studies and similar to those reported in US White women.Implications for Patient Care The burden of IBD in US Black women is high and similar to that of US White women.Competing Interest StatementAAY is a consultant for Janssen and receives research funding from Pfizer Medical Grants Program and Exact Sciences. HK has received grant funding from Pfizer and Takeda. HK has also received consulting fees from Takeda.Funding StatementNo direct funding for this study. Black Women’s Health Study is supported by U01 CA164974.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB at Boston University and Massachusetts General Hospital have approved this study. Protocol # 2022P000551I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData underlying the study cannot be made publicly available due to ethical concerns about patient confidentiality. Data will be made available to qualified researchers on request to BWHS@bu.edu .